Company Reports / Pfizer Inc.

COMPANY: Pfizer Inc.

INDEX RANK: 3rd

Total Impact Score: 9,712,455.95

Pfizer Inc. is ranked 3rd place in our index for 2015. Pfizer Inc.’s drugs have a total impact score of 9,712,455.95. Pfizer Inc. treats five diseases in our model - DSTB, MDR-TB, XDR-TB, P. falc malaria, and LF - with seven total drugs - Ethambutol (E or EMB), Ethionamide (Eto), Cycloserine (Cs), p-aminosalicylic acid (PAS), Diethylcarbamazine (DEC), Nelfinavir (NFV), and Doxycycline (D). Pfizer Inc. receives credit for one treatment against DS-TB - Ethambutol (E or EMB). This one drug averted 8,470,126.91 of the total DALYS for DS-TB, which is 25.00% of the worldwide DALYs that we estimate would have been lost due to DS-TB in 2015 in the absence of effective treatment. Pfizer Inc.’s drug portfolio placed it in a tie for 1st in terms of total averted DALYs for DS-TB. Pfizer Inc. receives credit for three treatments against MDR-TB - Cycloserine (Cs), Ethionamide (Eto), and p-aminosalicylic acid (PAS). These three drugs averted 1,213,914.04 of the total DALYS for MDR-TB, which is 60.70% of the worldwide DALYs that we estimate would have been lost due to MDR-TB in 2015 in the absence of effective treatment. Pfizer Inc.’s drug portfolio placed it 1st in terms of total averted DALYs for MDRTB. Pfizer Inc. receives credit for one treatment against XDR-TB - Cycloserine (Cs). This one drug averted 26,589.80 of the total DALYS for XDR-TB, which is 37.50% of the worldwide DALYs that we estimate would have been lost due to XDR-TB in 2015 in the absence of effective treatment. Pfizer Inc.’s drug portfolio placed it 1st in terms of total averted DALYs for XDR-TB. Pfizer Inc. receives credit for one treatment against P. falc malaria - Doxycycline (D). This one drug averted 1579.82 of the total DALYS for P. falc malaria, which is 0.0069% of the worldwide DALYs that we estimate would have been lost due to P. falc malaria in 2015 in the absence of effective treatment. Pfizer Inc.’s drug portfolio placed it 5th in terms of total averted DALYs for P. falc malaria. Pfizer Inc. receives credit for one treatment against LF - Diethylcarbamazine (DEC). This one drug averted 245.39 of the total DALYS for LF, which is 4.94% of the worldwide DALYs that we estimate would have been lost due to LF in 2015 in the absence of effective treatment. Pfizer Inc.’s drug portfolio placed it 3rd in terms of total averted DALYs for LF.

Company Score Breakdown:

Key Drugs

CYCLOSERINE (CS)

Cycloserine (Cs) an analogue of amino acid D-alanine,, is a Group C second-line agent used in the treatment of rifampicin-resistant and multidrug-resistant tuberculosis. Cs is, relative to other second-line treatments, weakly effective against TB and has a high toxicity profile. Side effects include acute psychosis and seizure. In 1956 Pfizer first applied for a patent for Cs.

DIETHYLCARBAMAZINE (DEC)

Diethylcarbamazine (Dec) is an anti-filarial drug used to treat many worm infections including Onchocerciasis and Schistosomiasis. Because of adverse reactions such as fever, hypotension, increased eosinophilia, proteinuria and splenomegaly, diethylcarbamazine is rarely used for treatment, and must only be done so in a regulated setting, such as a hospital. Diethylcarbamazine was discovered in 1947, and its mechanism of action is irreversible cytotoxic effect which leads to an inhibition of the parasite motility and viability. Pfizer was its most recent patent holder, but this patent has since expired.

DOXYCYCLINE (D)

Doxycycline (D): Doxycycline is a slow-acting treatment agent, and acts as an effective prophylactic against P. vivax and P. falc malaria when used in combination therapy with quinine, side effects may include fever, headaches, dizziness. Doxycycline was first patented by Pfizer in 1962.

ETHAMBUTOL (E)

Ethambutol (E) is a first line semisynthetic antibiotic used in the treatment of drug-susceptible tuberculosis and as an add-on agent in drug-resistant TB. Due to its high safety profile and broad antibiotic activity it is a companion drug in the core TB treatment regimen. Side effects include blurred vision and gastrointestinal upset. The earliest patent for E was by the American cyanamid Company in 1976 and is currently held by Pfizer.

ETHIONAMIDE (ETO)

Ethionamide (Eto) a thioamide antibiotic, is a Group C second-line agent used in the treatment of rifampicin-resistant and multidrug-resistant tuberculosis. Eto is moderately effective against TB but has a high toxicity profile. Side effects include seizure and blurred vision. It was first patented by Pfizer in 1959.

NELFINAVIR (NFV)

Nelfinavir (NFV) is a widely used protease inhibitor often combined with other reverse transcriptase inhibitors for the treatment of HIV, but is no longer recommended for use in the U.S. Major toxicity concerns include new-onset diabetes and ketoacidosis. It was developed by Agouron Pharmaceuticals and, in 1998, Agouron was sold to Warner Lambert, which later merged with Pfizer.

PAS (4-AMINOSALICYLIC ACID)

PAS (4-aminosalicylic acid) is used as an add-on agent to treat rifampicin-resistant and multidrugresistant tuberculosis. While PAS was first developed in 1902, its antituberculosis properties were not discovered until 1943. Due to its high toxicity it is rarely used and is in the WHO’s last group of recommended treatment for MDR-TB, Group D3. PAS was first patented by Pfizer in 1948.

Company Information

Pfizer Inc is a global pharmaceutical company headquartered in New York, NY and founded in 1849 by Charles Pfizer and Charles Erhart. Pfizer’s products delve into many therapeutic areas such as: pain management, respiratory, digestive, inflammation, immunology, rare disease, cardiovascular, oncology, and anti-infection. Major products include Lyrica®, Prevnar 13®, and Ibrance®. Pfizer works to reduce the disease burden with programs such as: the International Trachoma Initiative, co-founded in 1998 with the Edna McConnell Clark Foundation that treated over 100 million people in 2017, the Diflucan Partnership Program, launched in 2000, that has donated over 100 million treatments for HIV-related infection, and cash grants/investments through the Pfizer Foundation that funds initiatives aimed at improving health care delivery in low and middle income countries. Pfizer Inc. has over 90,000 employees in over 125 countries and earned a revenue of approximately $52.5 billion in 2017.

Company Report PDF

CONTACT US © 2017 GLOBAL HEALTH IMPACT